Company Name:
affymax_logo.gif
Affymax - Headquarters
Category:
Web Site:
Twitter:
n/a
Company Description:
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening

Source: CrunchBase


Headquarters: 4001 Miranda Avenue, Palo Alto, CA 94304
37.3996998, -122.13525379999999
Your Connections at Affymax:
Company News (powered by Google News)

Affymax (OTCMKTS:AFFY) Share Price Crosses Above 200 Day Moving Average of $0.02 - Riverton Roll
Posted on Sunday January 26, 2020

Affymax (OTCMKTS:AFFY) Share Price Crosses Above 200 Day Moving Average of $0.02  Riverton Roll


Rigel Pharmaceuticals (NASDAQ:RIGL) & Affymax (NASDAQ:AFFY) Head to Head Analysis - Riverton Roll
Posted on Saturday January 11, 2020

Rigel Pharmaceuticals (NASDAQ:RIGL) & Affymax (NASDAQ:AFFY) Head to Head Analysis  Riverton Roll


Head to Head Analysis: Affymax (OTCMKTS:AFFY) & Rigel Pharmaceuticals (OTCMKTS:RIGL) - Slater Sentinel
Posted on Thursday January 09, 2020

Head to Head Analysis: Affymax (OTCMKTS:AFFY) & Rigel Pharmaceuticals (OTCMKTS:RIGL)  Slater Sentinel


Affymax, once a promising biotech, is dissolving - FiercePharma
Posted on Tuesday June 24, 2014

Affymax, once a promising biotech, is dissolving  FiercePharma


Affymax Is Done. RIP. - TheStreet.com
Posted on Monday February 25, 2013

Affymax Is Done. RIP.  TheStreet.com


Affymax Cuts 230 Jobs, Mulls Bankruptcy, After Drug Withdrawal - Xconomy
Posted on Monday March 18, 2013

Affymax Cuts 230 Jobs, Mulls Bankruptcy, After Drug Withdrawal  Xconomy


Affymax CEO steps down as restructuring firm steps in - San Francisco Business Times - San Francisco Business Times
Posted on Tuesday May 14, 2013

Affymax CEO steps down as restructuring firm steps in - San Francisco Business Times  San Francisco Business Times


Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen - Seeking Alpha
Posted on Wednesday August 28, 2013

Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen  Seeking Alpha


Affymax Lives to Fight Another Day, In Bid to Challenge Amgen's Monopoly - Xconomy
Posted on Monday August 09, 2010

Affymax Lives to Fight Another Day, In Bid to Challenge Amgen's Monopoly  Xconomy


Stocks That Hit 52-Week Highs On Thursday - Benzinga
Posted on Thursday January 16, 2020

Stocks That Hit 52-Week Highs On Thursday  Benzinga


Stocks That Hit 52-Week Highs On Friday - Benzinga
Posted on Friday January 17, 2020

Stocks That Hit 52-Week Highs On Friday  Benzinga


Affymax Hires New CEO, Former Genentecher, to Complete FDA Push With Anemia Drug - Xconomy
Posted on Thursday January 06, 2011

Affymax Hires New CEO, Former Genentecher, to Complete FDA Push With Anemia Drug  Xconomy


Affymax breaks Amgen's anemia drug monopoly with ESA approval - FierceBiotech
Posted on Tuesday March 27, 2012

Affymax breaks Amgen's anemia drug monopoly with ESA approval  FierceBiotech


Spero Announces Appointment of Cynthia Smith to its Board of Directors - GlobeNewswire
Posted on Tuesday March 19, 2019

Spero Announces Appointment of Cynthia Smith to its Board of Directors  GlobeNewswire


Affymax (OTCMKTS:AFFY) Stock Price Crosses Above 200-Day Moving Average of $0.02 - Riverton Roll
Posted on Tuesday December 31, 2019

Affymax (OTCMKTS:AFFY) Stock Price Crosses Above 200-Day Moving Average of $0.02  Riverton Roll

Videos
map_pin_affymax.png
United States
SF Bay Area
Peninsula
2011-12-27
191
building.png
No
Affymax
No
No
Affymax
Palo Alto
Affymax
affymax
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening
http://www.crunchbase.com/organization/affymax?&utm_source=odm_csv&utm_medium=export&utm_campaign=dataset
Active
CrunchBase
Affymax
sf-bay-area
company